Grundinformationen
- Standard-SMILES
NCCC(O)(P(=O)([O-])O)P(=O)([O-])O.[Na+].[Na+]- InChIKey
CEYUIFJWVHOCPP-UHFFFAOYSA-L- Summenformel
- C3H9NNa2O7P2
- Durchschnittliche Molmasse
- 279,03 g/mol
- Monoisotopische Masse
- 278,96496345
Überblick
Pamidronate Disodium is the disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.
Namen und Bezeichner
- Bevorzugter Name
- Pamidronate Disodium Anhydrous
- IUPAC
- disodium;[3-amino-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate
Namen und Synonyme
PAMIDRONATE DISODIUM57248-88-1Disodium pamidronateAminomuxPamidronic acid disodium saltPamidronate disodium anhydrousC7S8VWP5DHGCP-23339ADTXSID5042667Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium saltNSC-722600CGP-23339AE
Weitere Namen anzeigen
NSC720699RefChem:57112DTXCID3022667260-647-18742T8ZQZACGP 23339AEPamidronate disodium pentahydratePhosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt, pentahydrate
Datenbank-Bezeichner
- CAS
57248-88-1- PubChem CID
- 73351
- DTXSID
DTXSID5042667- ChEMBL
CHEMBL3989401、CHEMBL676- UNII
- C7S8VWP5DH
- EC Number
- 260-647-1
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 167 Ų
- H-Brücken-Donoren
- 4
- H-Brücken-Akzeptoren
- 8
- Frei drehbare Bindungen
- 4
- Schwere Atome
- 15
- Formalladung
- 0
- Komplexität
- 238
Experimentelle und physikochemische Eigenschaften
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P308+P316, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 6 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Regulatory InformationPhosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesAcute Tox. 4 (100%)
Toxikologische Informationen
TreatmentIf overdosage occurs, symptomatic hypocalcemia could also result; such patients should be treated with short-term intravenous calcium. (L1712)
Health EffectsRare cases of uveitis, iritis, scleritis, and episcleritis have been reported, including one case of scleritis, and one case of uveitis upon separate rechallenges.
Exposure RoutesParenteral (intravenous).
Plasma concentration rises rapidly upon IV administration.
Toxicity Summary
The mechanism of action of pamidronate is inhibition of bone resorption. Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Pamidronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Signs and SymptomsSide effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Pamidronate disodium
Ambiguous-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Chemie und Industrie
Pharmakologische Informationen
Metabolism/Metabolites
Pamidronate is not metabolized and is exclusively eliminated by renal excretion. Route of Elimination: Pamidronate is not metabolized and is exclusively eliminated by renal excretion. Half Life: The mean ± SD elimination half-life is 28 ± 7 hours
FDA Pharmacological Classification
PAMIDRONATE DISODIUM
Diphosphonates [CS]; Bisphosphonate [EPC]
MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Verwendung und Herstellung
Uses
Pamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma. For the treatment of moderate or severe hypercalcemia associated with malignancy
Zugehörige Reaktionen
5
Verknüpfte Notizen
Wird geladen…